Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1575 of 3546 entries
View as:

Efficacy and Safety Study of Nicotine Mint Lozenge (2mg and 4mg) in Smoking Cessation

Phase: N/A Priority: Normal
NCT ID: NCT00985985 Org: User:
Start: 05/31/09 End: 03/31/11 Due: 03/31/12

Evaluation of Single and Repeat Doses of GSK729327 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00448890 Org: User:
Start: 11/30/06 End: 01/31/09 Due: 01/31/10

Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis

Phase: N/A Priority: Normal
NCT ID: NCT01262898 Org: User:
Start: 05/03/11 End: 02/26/13 Due: 02/26/14

Patient Tolerability Study of GSK163090

Phase: N/A Priority: Normal
NCT ID: NCT00559299 Org: User:
Start: 11/30/07 End: 06/30/08 Due: 06/30/09

A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00942162 Org: User:
Start: 08/14/09 End: 04/01/15 Due: 04/01/16

Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

Phase: N/A Priority: Normal
NCT ID: NCT01772134 Org: User:
Start: 01/01/13 End: 07/22/13 Due: 07/22/14

Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT04246047 Org: User:
Start: 05/07/20 End: 06/19/26 Due: 06/19/27

Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02034123 Org: User:
Start: 02/04/14 End: 04/18/17 Due: 04/18/18

A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Evaluate GSK1614235, a New Glucose Lowering Drug to Treat Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT00976261 Org: User:
Start: 10/17/09 End: 09/05/10 Due: 09/05/11

Cross-sectional Study for Identification and Description of Severe Asthma Patients

Phase: N/A Priority: Normal
NCT ID: NCT02293265 Org: User:
Start: 12/31/14 End: 05/31/15 Due: 05/31/16

A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambulant DMD Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01128855 Org: User:
Start: 07/12/10 End: 10/25/11 Due: 10/25/12

A Clinical Trial to Study the Impact of a Nutritional Beverage on Tests of Memory in Healthy Preschool Age Children

Phase: N/A Priority: Normal
NCT ID: NCT02177942 Org: User:
Start: 06/20/14 End: 06/01/15 Due: 06/01/16

A Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Study in Men With Premature Ejaculation

Phase: N/A Priority: Normal
NCT ID: NCT01021553 Org: User:
Start: 12/23/09 End: 05/05/11 Due: 05/05/12

Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine

Phase: N/A Priority: Normal
NCT ID: NCT01309646 Org: User:
Start: 03/04/11 End: 02/24/12 Due: 02/24/13

Phase I Study of Pyrimethamine in Healthy Japanese and Caucasian Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03258762 Org: User:
Start: 09/25/17 End: 11/19/17 Due: 11/19/18

Patient-Reported Outcome Measurement Information System (PROMIS) Physical Function

Phase: N/A Priority: Normal
NCT ID: NCT03351140 Org: User:
Start: 12/20/17 End: 05/08/20 Due: 05/08/21

Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa

Phase: N/A Priority: Normal
NCT ID: NCT00381472 Org: User:
Start: 06/30/03 End: 12/31/04 Due: 12/31/05

A Study to Examine the Pharmacodynamic Effects of GSK1034702 on Neurophysiological Biomarkers of Cognition in Nicotine Abstained Otherwise Healthy Smokers

Phase: N/A Priority: Normal
NCT ID: NCT01371799 Org: User:
Start: 12/17/09 End: 06/18/10 Due: 06/18/11

Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00290355 Org: User:
Start: 05/28/02 End: 07/19/11 Due: 07/19/12

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients

Phase: N/A Priority: Normal
NCT ID: NCT02130635 Org: User:
Start: 07/31/14 End: 08/18/15 Due: 08/18/16

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Poliorix™ Vaccine

Phase: N/A Priority: Normal
NCT ID: NCT01021293 Org: User:
Start: 11/28/09 End: 07/05/10 Due: 07/05/11

A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01938443 Org: User:
Start: 11/18/13 End: 06/23/16 Due: 06/23/17

Dose Proportionality Study: Blood Levels of Fluticasone Furoate (FF) and Vilanterol (VI) Following Different Doses of FF/VI Via an Inhaler

Phase: N/A Priority: Normal
NCT ID: NCT01213849 Org: User:
Start: 10/04/10 End: 11/25/10 Due: 11/25/11

Effects Of GW876008 On The Bowel In Patients With Irritable Bowel Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT00385099 Org: User:
Start: 12/08/06 End: 10/15/07 Due: 10/15/08

Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older

Phase: N/A Priority: Normal
NCT ID: NCT01165177 Org: User:
Start: 08/02/10 End: 07/27/15 Due: 07/27/16